Efficiency of anti-vascular endothelial growth factor drug switch in patients who did not respond to a series of bevacizumab injections
Switching anti-VEGF agents appears anatomically beneficial in nonresponding eyes. Notably, the inclusion of a control group continuing bevacizumab despite poor response allows for a more reliable evaluation of treatment efficacy, addressing a key limitation of prior studies and contributing to the evidence-based rationale for agent switching.
Authors
- R Sagiv (ORCID: https://orcid.org/0000-0003-0442-0339)
- Hadar Naidorf Rosenblatt (ORCID: https://orcid.org/0000-0002-2015-8767)
- Ziv Rotfogel
- Shalhevet Goldfeather Ben-Zaken
- Efrat Zamir (ORCID: https://orcid.org/0000-0002-2073-3944)
- Aya Altarescu (ORCID: https://orcid.org/0000-0002-2678-1955)
Institutions
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Kaplan Medical Center (IL)
- Assaf Harofeh Medical Center (IL)
Publication Details
- Journal
- Indian Journal of Ophthalmology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.4103/ijo.ijo_1740_25
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00